Cantor Fitzgerald Reiterates Neutral on Bristol-Myers Squibb, Maintains $50 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Olivia Brayer has reiterated a Neutral rating on Bristol-Myers Squibb (NYSE:BMY) and maintained a $50 price target.
September 16, 2024 | 3:28 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Cantor Fitzgerald has reiterated a Neutral rating for Bristol-Myers Squibb, maintaining a $50 price target. This suggests that the analyst does not expect significant short-term price movement.
The reiteration of a Neutral rating and maintenance of the $50 price target by Cantor Fitzgerald indicates that the analyst does not foresee significant changes in the stock's performance in the short term. This suggests stability in the stock price, aligning with the Neutral outlook.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100